05.14.26 -- Vaccine Platform Vs. CDMO Model: Outsourcing Lessons For All Biopharma

An experienced industry leader shares insights on how biosimilars are reshaping healthcare through scale, manufacturing discipline, supply reliability, and long‑term commercial strategy.

Understanding drug substance vs. drug product responsibilities helps avoid regulatory issues, technical risks, and delays while improving planning, scalability, and GMP‑compliant execution.

Delve into the specific advantages of dual-sourcing in pharmaceutical fill/finish, exploring how this approach can bolster supply chain resilience, increase capacity, and accelerate commercialization.

A practical guide to applying Quality by Design to outsourced GXP operations, helping virtual and hybrid sponsors maintain regulatory control, inspection readiness, and accountability.

Particle counts don’t manage risk. Biologics need particle ID and forensic insight to separate benign artifacts from real threats and guide early decisions.

Delve into the complexities of decisions to gain insights from biopharma developers and a CDMO. Learn about their mutual interest in achieving scale-up and strategies for avoiding common pitfalls.

Uncover how switching from LAL to rFC can enhance sustainability, improve testing reliability, and strengthen supply-chain resilience in endotoxin testing.

A transposon‑enabled cell line development strategy streamlines upstream optimization, shortening timelines while improving consistency, yield, and quality across recombinant protein modalities.

A partnership can deliver more than process support. Transparency, regulatory expertise, and IP protection are benefits that safeguard your autonomy and innovation while enabling global success.

Kimberly Shepard, Ph.D., principal engineer in R&D, addresses the challenges associated with spray-drying late-stage lung cancer treatments, including proteins, peptides, and mAbs.

Annex 1’s updated CCS framework calls for a holistic contamination strategy. Assimilate how manufacturers can apply it to non-sterile sites and legacy facilities using tailored risk-based approaches.

Explore how fostering a strong safety culture — rooted in accountability, collaboration, and proactive risk management — can drive operational excellence and long-term success in biopharmaceuticals.

Here, we review several challenges in biologics analysis and take a closer look at the advanced tools and methods being utilized to improve biophysical analysis reliability and efficiency.

Navigate the path from concept to clinical reality by partnering with a CDMO that can provide the regulatory, clinical, and CMC expertise needed to move your therapeutic forward.

Look at how this solid-state HDX-MS is being used to revolutionize the prediction of stability for IgG-based antibody drug conjugates and enhance ADC development processes.

Antibody–drug conjugates combine monoclonal antibodies, linkers, and cytotoxins, requiring sensitive analytics, cleaning validation, and flexible platforms to manage manufacturing and contamination risks.